71 related articles for article (PubMed ID: 8891155)
1. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci.
Schwalbe RS; McIntosh AC; Qaiyumi S; Johnson JA; Johnson RJ; Furness KM; Holloway WJ; Steele-Moore L
Antimicrob Agents Chemother; 1996 Oct; 40(10):2416-9. PubMed ID: 8891155
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitory and bactericidal activities and postantibiotic effects of LY333328 and ampicillin used singly and in combination against vancomycin-resistant Enterococcus faecium.
Baltch AL; Smith RP; Ritz WJ; Bopp LH
Antimicrob Agents Chemother; 1998 Oct; 42(10):2564-8. PubMed ID: 9756756
[TBL] [Abstract][Full Text] [Related]
3. Investigation of Staphylococcus strains with heterogeneous resistance to glycopeptides in a Turkish university hospital.
Nakipoglu Y; Derbentli S; Cagatay AA; Katranci H
BMC Infect Dis; 2005 May; 5():31. PubMed ID: 15871748
[TBL] [Abstract][Full Text] [Related]
4. Influence of human serum on pharmacodynamic properties of an investigational glycopeptide, LY333328, and comparator agents against Staphylococcus aureus.
Zhanel GG; Kirkpatrick ID; Hoban DJ; Kabani AM; Karlowsky JA
Antimicrob Agents Chemother; 1998 Sep; 42(9):2427-30. PubMed ID: 9736576
[TBL] [Abstract][Full Text] [Related]
5. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.
Tenover FC; Lancaster MV; Hill BC; Steward CD; Stocker SA; Hancock GA; O'Hara CM; McAllister SK; Clark NC; Hiramatsu K
J Clin Microbiol; 1998 Apr; 36(4):1020-7. PubMed ID: 9542929
[TBL] [Abstract][Full Text] [Related]
6. Characterisation of the selective binding of antibiotics vancomycin and teicoplanin by the VanS receptor regulating type A vancomycin resistance in the enterococci.
Hughes CS; Longo E; Phillips-Jones MK; Hussain R
Biochim Biophys Acta Gen Subj; 2017 Aug; 1861(8):1951-1959. PubMed ID: 28511809
[TBL] [Abstract][Full Text] [Related]
7. Low frequencies of resistance among Staphylococcus and Enterococcus species to the bactericidal DNA polymerase inhibitor N(3)-hydroxybutyl 6-(3'-ethyl-4'-methylanilino) uracil.
Butler MM; Skow DJ; Stephenson RO; Lyden PT; LaMarr WA; Foster KA
Antimicrob Agents Chemother; 2002 Dec; 46(12):3770-5. PubMed ID: 12435675
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic compounds targeting Lipid II for antibacterial purposes.
Malin JJ; de Leeuw E
Infect Drug Resist; 2019; 12():2613-2625. PubMed ID: 31692545
[TBL] [Abstract][Full Text] [Related]
9. Oritavancin for acute bacterial skin and skin structure infections.
Messina JA; Fowler VG; Corey GR
Expert Opin Pharmacother; 2015 May; 16(7):1091-8. PubMed ID: 25803197
[TBL] [Abstract][Full Text] [Related]
10. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections.
Arias CA; Mendes RE; Stilwell MG; Jones RN; Murray BE
Clin Infect Dis; 2012 Apr; 54 Suppl 3(Suppl 3):S233-8. PubMed ID: 22431854
[TBL] [Abstract][Full Text] [Related]
11. A vancomycin photoprobe identifies the histidine kinase VanSsc as a vancomycin receptor.
Koteva K; Hong HJ; Wang XD; Nazi I; Hughes D; Naldrett MJ; Buttner MJ; Wright GD
Nat Chem Biol; 2010 May; 6(5):327-9. PubMed ID: 20383152
[TBL] [Abstract][Full Text] [Related]
12. Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia.
Rubino CM; Van Wart SA; Bhavnani SM; Ambrose PG; McCollam JS; Forrest A
Antimicrob Agents Chemother; 2009 Oct; 53(10):4422-8. PubMed ID: 19635952
[TBL] [Abstract][Full Text] [Related]
13. Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: study of antibiotic combinations.
Nguyen HA; Denis O; Vergison A; Tulkens PM; Struelens MJ; Van Bambeke F
Antimicrob Agents Chemother; 2009 Apr; 53(4):1443-9. PubMed ID: 19188397
[TBL] [Abstract][Full Text] [Related]
14. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
Higgins DL; Chang R; Debabov DV; Leung J; Wu T; Krause KM; Sandvik E; Hubbard JM; Kaniga K; Schmidt DE; Gao Q; Cass RT; Karr DE; Benton BM; Humphrey PP
Antimicrob Agents Chemother; 2005 Mar; 49(3):1127-34. PubMed ID: 15728913
[TBL] [Abstract][Full Text] [Related]
15. Newer treatment options for skin and soft tissue infections.
Raghavan M; Linden PK
Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625
[TBL] [Abstract][Full Text] [Related]
16. Glycopeptide antibiotics: from conventional molecules to new derivatives.
Van Bambeke F; Van Laethem Y; Courvalin P; Tulkens PM
Drugs; 2004; 64(9):913-36. PubMed ID: 15101783
[TBL] [Abstract][Full Text] [Related]
17. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis.
Cabellos C; Fernà ndez A; Maiques JM; Tubau F; Ardanuy C; Viladrich PF; Liñares J; Gudiol F
Antimicrob Agents Chemother; 2003 Jun; 47(6):1907-11. PubMed ID: 12760866
[TBL] [Abstract][Full Text] [Related]
18. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
19. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis.
Lefort A; Saleh-Mghir A; Garry L; Carbon C; Fantin B
Antimicrob Agents Chemother; 2000 Nov; 44(11):3017-21. PubMed ID: 11036016
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin-resistant enterococci.
Cetinkaya Y; Falk P; Mayhall CG
Clin Microbiol Rev; 2000 Oct; 13(4):686-707. PubMed ID: 11023964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
